Gilead Sciences (NASDAQ:GILD) Insider Johanna Mercier Sells 28,000 Shares of Company Stock

Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $170.55, for a total transaction of $4,775,400.00. Following the completion of the transaction, the insider owned 110,684 shares in the company, valued at approximately $18,877,156.20. This represents a 20.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Johanna Mercier also recently made the following trade(s):

  • On Thursday, October 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The shares were sold at an average price of $156.22, for a total value of $468,660.00.
  • On Tuesday, September 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The shares were sold at an average price of $144.22, for a total value of $432,660.00.

Gilead Sciences Stock Performance

NASDAQ GILD traded up $2.68 on Tuesday, reaching $170.26. The stock had a trading volume of 6,280,613 shares, compared to its average volume of 6,456,805. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.22 and a current ratio of 1.38. Gilead Sciences, Inc. has a 1 year low of $116.88 and a 1 year high of $176.58. The business has a 50 day moving average price of $155.90 and a 200 day moving average price of $142.09.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. The company had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The business’s quarterly revenue was up 6.8% on a year-over-year basis. During the same period last year, the business earned $2.47 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post -0.97 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s payout ratio is currently -103.80%.

Institutional Investors Weigh In On Gilead Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. HighMark Wealth Management LLC lifted its position in Gilead Sciences by 34.1% in the third quarter. HighMark Wealth Management LLC now owns 291 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 74 shares during the period. Ancora Advisors LLC boosted its stake in Gilead Sciences by 5.7% during the third quarter. Ancora Advisors LLC now owns 128,449 shares of the biopharmaceutical company’s stock worth $19,145,000 after buying an additional 6,984 shares in the last quarter. Capstone Financial Advisors Inc. bought a new stake in Gilead Sciences in the 3rd quarter valued at $224,000. Allworth Financial LP increased its holdings in Gilead Sciences by 10.9% in the 3rd quarter. Allworth Financial LP now owns 52,348 shares of the biopharmaceutical company’s stock valued at $7,802,000 after buying an additional 5,156 shares during the period. Finally, MOKAN Wealth Management Inc. increased its holdings in Gilead Sciences by 41.4% in the 3rd quarter. MOKAN Wealth Management Inc. now owns 14,699 shares of the biopharmaceutical company’s stock valued at $2,191,000 after buying an additional 4,300 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GILD has been the topic of several analyst reports. Bank of America increased their target price on shares of Gilead Sciences from $168.00 to $172.00 and gave the stock a “buy” rating in a research report on Tuesday, October 20th. Weiss Ratings raised Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. Royal Bank Of Canada upped their price target on Gilead Sciences from $126.00 to $131.00 and gave the stock a “sector perform” rating in a research note on Friday, October 30th. Cantor Fitzgerald increased their price objective on Gilead Sciences from $155.00 to $175.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Finally, Morgan Stanley raised their price objective on Gilead Sciences from $163.00 to $183.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Twenty-three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $171.63.

View Our Latest Stock Analysis on Gilead Sciences

Top Gilead Sciences Stories

These are some of the GILD stories that stood out recently:

  • Neutral Sentiment: Gilead executives appeared at the Jefferies and UBS healthcare conferences, but the provided headlines do not identify specific new guidance or announcements that would change the investment outlook. Jefferies conference transcript
  • Negative Sentiment: Barclays maintained an equal-weight/hold stance while raising its price target to $160, still below the $170.26 price cited in the stock-performance information. That gap highlights valuation risk after GILD’s strong run. Barclays rating
  • Negative Sentiment: A separate report said Zacks Research forecast lower earnings, adding a cautious estimate revision to the mix. Zacks earnings forecast

Gilead Sciences Company Profile

(Get Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Recommended Stories

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.